BioSpace News Archive

Business

BIOREFERENCE LABORATORIES SELECTED AS PREFERRED LABORATORY PROVIDER BY THE IPA ASSOCIATION OF AMERICA

BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data analytics for its members’ patients.

August 1, 2019

·

4 min read

BioForest

Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers

Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), today announced that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved the clonoSEQ®Assay for the detection and monitoring of minimal residual disease (MRD) in patients with B-cell blood cancers

August 1, 2019

·

5 min read

Policy

Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Cardinal Health, Inc. and Certain of Its Senior Executives

Bernstein Litowitz Berger & Grossmann LLP announced that it filed a securities class action lawsuit on behalf of its client Louisiana Sheriffs’ Pension & Relief Fund against Cardinal Health, Inc., and certain of the Company’s senior executives.

August 1, 2019

·

4 min read

CPhI & P-MEC China 2019 celebrated its 19th edition as a great success

An audio-visual feast of pharmaceuticals, a fortissimo in the pharmaceutical era of China

August 1, 2019

·

11 min read

Drug Development

Novartis’ Kisqali Effective in Postmenopausal Women with Breast Cancer

Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis.

August 1, 2019

·

3 min read

·

Mark Terry

Genetown

Boston’s Vida Ventures Snags $600 Million for New Life Science Fund

Vida launched in April 2017 and already has over a $1 billion in funds. It has invested in 14 companies, and three have launched initial public offerings.

August 1, 2019

·

3 min read

·

Mark Terry

Business

Exelixis Bolsters Pipeline in Deal with India’s Aurigene

Under the terms of the deal, Exelixis is paying Aurigene $10 million up front for exclusive options to license three existing programs. The two companies will then launch three drug discovery programs led by Aurigene on mutually agreed-upon targets.

August 1, 2019

·

3 min read

·

Mark Terry

BioSpace Global Roundup, August 1

Companies from across the globe share business and pipeline updates.

August 1, 2019

·

2 min read

·

Ellen Bombela

BioCapital

Study: Patients’ Immune Reactions to Checkpoint Inhibitors May Reflect Better 5-Year Survival Rates

Researchers with Johns Hopkins Kimmel Cancer Center recently published research that followed 270 cancer patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab). The research reported impressive improvements in five-year survival rates.

August 1, 2019

·

2 min read

·

Mark Terry

Policy

UC-Berkeley Rekindles U.S. Patent Dispute with the Broad Institute over CRISPR

Although the lawsuits over who owns the rights to gene editing technique CRISPR seemed to be mostly settled in September 2018, a recent dispute between the University of California and the Cambridge, Massachusetts-based Broad Institute suggested the battles aren’t done yet.

August 1, 2019

·

3 min read

·

Mark Terry